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httpsWHAT THIS PAPER ADDS
Analysis of the performance of modern stent grafts is necessary as earlier generation stent grafts are associated
with an increased need for secondary interventions. Five year follow up of patients treated with the Endurant
stent graft in the ENGAGE registry demonstrates better survival and lower rates of endoleaks, stent migration,
and re-intervention. Longer term follow up to 10 years will be necessary to compare fully the advantages of
endovascular aneurysm repair against open repair. However, these mid-term results show the Endurant stent
graft was successful in treating a large cohort of patients with a wide range of anatomies.Objective/background: Endovascular abdominal aortic aneurysm repair (EVAR) is commonly used to treat
abdominal aortic aneurysm (AAA). However, the incidence of long-term complications and the need for re-
interventions after EVAR remain a concern. Newer generation stent grafts have encouraging short and mid-
term outcomes, but thorough analysis of their long-term performance is necessary.
Methods: The ENGAGE registry includes a total of 1263 patients with AAA enrolled from March 2009 to April
2011 at 79 centres across 30 countries. The aim of this study is to present standard EVAR outcomes in the
registry after ﬁve years.
Results: A signiﬁcant proportion of the ENGAGE patients presented with challenging features, such as 15.2% with
an AAA diameter >7 cm, 12.0% with proximal neck lengths <15 mm, and 10.2% with infrarenal neck angles
>60. Of the 1263 enrolled subjects, 17.8% were implanted outside of the instructions for use for the device.
At the ﬁve year follow up, the KaplaneMeier overall survival rate was 67.4% and the freedom from aneurysm
related mortality was 97.8%. Freedom from aneurysm rupture, secondary procedures, and conversion to open
repair at ﬁve years were 98.6%, 84.3%, and 97.9% respectively. The ﬁve year freedom from type IA endoleaks
was 95.2% and for type III endoleaks 97.4%. Aneurysm sac diameter at ﬁve years was observed to have
either decreased 5 mm in diameter or remained stable in 89.4% of the patients.
Conclusion: Five year follow up of patients in the ENGAGE registry demonstrates sustained safety, effectiveness,
and durability in an international cohort that is reﬂective of real world experience. Additional follow up is
expected through to 10 years.Keywords: ENGAGE, Endurant, EVAR, Long-term outcomes
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Endovascular abdominal aortic aneurysm repair (EVAR) has
shown large improvements in clinical safety and effective-
ness for the treatment of abdominal aortic aneurysms
(AAA) since its initial introduction.1,2 Today EVAR is well
established and in many cases the preferred option because
both short and mid-term outcomes are as good as or better
176 Joep A.W. Teijink et al.than open surgical repair (OSR). However, the “Achilles
heel” of EVAR is the incidence of mid and long-term com-
plications resulting in the need for conversion to OSR or
endovascular re-intervention.3e6 For example, long-term
follow up in the EVAR 1 trial, as well as a 2017 meta-
analysis,7e9 show earlier generation AAA stent grafts have a
higher risk of migration. Other earlier studies have also
suggested erosion of the short-term beneﬁt of EVAR over
OSR over time.3,4,10e13
To address these concerns, there have been many tech-
nological advances in stent graft design to improve ﬁxation,
deployment, and applicability to more complex anatomies.14
Recent literature suggests that newer generation stent grafts
have lower rates of complications and re-interventions.15e17
To truly assess the performance of newer generation stent
grafts, it is necessary to use current registries, which include
a wider patient population than the selective population in
clinical trials. While registries may have some inherent data
collection limitations, carefully designed observational
studies can provide evidence comparable to randomised
controlled trials (RCTs).18,19 The Endurant Stent Graft Natural
Selection Global Postmarket Registry (ENGAGE) is a global,
prospective multicentre registry evaluating the Endurant
stent graft system (Medtronic, Santa Rosa, CA, USA) and is
the largest registry for any single EVAR stent graft.20 Stok-
mans et al. published the peri-operative, 30 day, and interim
one year results,21 as well as a comparison between symp-
tomatic and asymptomatic AAAs,22 from the ENGAGE reg-
istry. Other analyses of the ENGAGE registry have
investigated outcomes for octogenarians, differences due to
sex, and higher risk anatomies and conditions.23e30 The aim
of the current study is to report the ﬁve year results of the
ENGAGE registry and assess long-term outcomes.METHODS
Full methodological details of the ENGAGE registry
(NCT00870051) and data collection rationale have been
published previously,21,31 as have the technical speciﬁca-
tions of the Endurant stent graft system.20 Brieﬂy, ENGAGE
is an observational, non-randomised, prospective “all
comer” registry. Sites were encouraged to consecutively
enrol patients, or at least blocks of ﬁve patients, to mini-
mise selection bias. Inclusion criteria were minimal and
accepted patients who fell outside of the instructions for
use (IFU) guidance. Select exclusion criteria were proba-
bility of non-adherence to follow up requirements, or
concurrent participation in another trial that might
confound results (Table S1). To date, the registry has
enrolled 1263 patients at 79 centres in 30 countries
spanning six continents.
Initially annual follow up visits were planned for ﬁve
years, now extended through to 10 years of follow up at
most of the centres. The ENGAGE registry did not require
speciﬁc tests or procedures that fall outside routine hospital
practices, and computed tomography (CT) with contrast
was the recommended imaging modality during follow up
visits. Patients with impaired renal function or contrastintolerance were recommended to have combinations of
Doppler ultrasound, CT without contrast, or magnetic
resonance imaging/angiography. Robust registry monitoring
consists of 100% data management review, extensive data
monitoring with all end points reviewed, and an indepen-
dent clinical event committee adjudicating major adverse
events within 30 days, and all deaths. Most participating
ENGAGE registry sites received approval of the protocol and
consent form by their appropriate local ethics committee.
As this was a registry protocol that did not impose any
additional interventions or changes to standard care prac-
tices, some sites did not require ethical committee approval
or only required for a notiﬁcation to their institutional re-
view board. Informed consent for authorisation of data
release was required as part of the trial participation and
was obtained from all patients at the time of enrolment.
The ENGAGE registry adheres to the Declaration of Helsinki
and applicable local regulations. Furthermore, the registry
was conducted with sections of ISO 14155, MEDDEV 2.12-2,
and the International Conference on Harmonisation Good
Clinical Practice as guidance.
Statistical analysis
This was a ﬁve year follow up analysis of the data in the
ENGAGE registry database. Patient baseline characteristics,
aneurysm characteristics, and risk factors are presented for
the 1263 patients as a mean  SD for continuous variables.
Percentage of patients was used for categorical variables
such as changes in aneurysm diameter. Outcomes such as
all cause mortality, aneurysm mortality, freedom from
endoleak, migration, AAA rupture, secondary endovascular
interventions, and so on, through to ﬁve years were
assessed with survival analyses. All variables are reported
descriptively without hypothesis testing as this was a reg-
istry analysis and not a RCT. All analyses were performed
using SAS 9.4 (SAS Institute Inc, Cary, NC, USA).
RESULTS
Baseline and procedural results
Of the 1263 patients enrolled, compliance with clinical and
imaging follow up was 87.8% and 73.7% at ﬁve years,
respectively. Baseline and procedural results are included in
the supplementary material (Tables S2 and S3) and in the
ENGAGE early results publication.21 To summarise, the
cohort consisted of mostly elderly males with multiple risk
factors and comorbidities. ENGAGE patients presented with
challenging anatomical features, including 15.2% with an
AAA diameter >7 cm, 12.0% with proximal neck lengths
<15 mm, 10.2% with infrarenal neck angles >60, and
17.8% implanted outside the IFU. The technical and clinical
success rates were 99.0% and 97.6%, respectively, with no
deaths during the implantation procedure.
Five year outcomes: endoleaks and technical observations
Freedom from type IA endoleaks was 95.2% with a 95%
conﬁdence interval (CI) of 93.4e97.0% (Fig. 1). The ﬁve year
freedom from any endoleak, type IB endoleaks, and type III
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Figure 1. Cumulative Kaplan-Meier estimate of freedom from type
Ia endoleaks through to ﬁve years. Number at risk represents pa-
tients at risk at beginning of interval; estimate made at end of time
interval.
Five Year Outcomes of the Endurant Stent Graft 177endoleaks was 68.6% (95% CI 65.3e71.9%), 95.9% (95% CI
94.5e97.3%), and 97.4% (95% CI 96.2e98.6%), respectively.
There was one post-operative migration of the stent graft’s
main body occurring in year 4, resulting in 99.8% of patients
being free from this event after ﬁve years. A second patient
had an observed graft migration on day 1870, which was
not included in the time to event curve because of the
1 826 day cut off. A summary of technical observations, as
well as events such as conversions to open repair and
rupture, is in Table 1.Table 1. Technical observations and major events during follow up
Technical Observations
(TOs)1
At 1 year % (m/n)2 At 2 years % (m/n)2
1 Technical observations 13.5% (146/1079) 13.0% (117/902)
Limb migration 0.1% (1/819) 0.9% (5/573)
Main body migration 0.0% (0/819) 0.0% (0/573)
Stent graft kinking 0.2% (2/805) 0.4% (2/560)
Suprarenal bare stent
fracture
0.0% (0/819) 0.0% (0/573)
Stent graft occlusion 1.7% (17/1017) 0.4% (3/833)
Stent graft stenosis 1.1% (11/1017) 0.5% (4/834)
Endoleak 10.4% (108/1034) 11.0% (94/856)
Type I 0.5% (5/1034) 1.2% (10/856)
Type IA 0.3% (3/1034) 0.5% (4/856)
Type IB 0.2% (2/1034) 0.7% (6/856)
Type II 9.2% (95/1034) 8.4% (72/856)
Type III 0.2% (2/1034) 0.6% (5/856)
Type IV 0.1% (1/1034) 0.0% (0/856)
Major Events3 0-365 Days % (m/n)4 366-731 Days % (m/n)4 732-1096
Conversion to open
surgery
0.6% (7/1263) 0.3% (3/1150) 0.1% (1/
Aneurysm Rupture 0.2% (2/1263) 0.2% (2/1150) 0.2% (2/
1
Technical observations were assessed for Implanted Subjects
2 m ¼ number of implanted subjects who experienced the corresponding t
subjects who had valid images for each speciﬁc assessment of technical o
occlusion, stenosis, and migration (after 1 year) the subjects who exper
excluded from both the denominator and numerator at the current visit.
3 Major events were assessed for the Intent to Treat Subjects.
4 m ¼ number of subjects having corresponding event within given time pe
or entered the given time period.All cause mortality and aneurysm related mortality within
ﬁve years
The KaplaneMeier estimate of overall survival through to
ﬁve years was 67.4% with a 95% CI of 64.1e70.7% (Fig. 2).
The KaplaneMeier estimate of freedom from aneurysm
related mortality through to ﬁve years was 97.8% (95% CI
96.8e98.8%), with six deaths occurring from years two to
ﬁve. Of the 95 all cause deaths in the ﬁrst year, 19 were
aneurysm related. Of the 375 all cause deaths through to
ﬁve years, 25 were aneurysm related.Rupture, secondary endovascular procedures, and
conversion to OSR
Freedom from secondary endovascular procedure was
84.3% (95% CI 81.4e87.2%) through to ﬁve years (Fig. 3).
Indications for secondary endovascular procedures were
type I endoleak (23%), type II endoleak (21%), stent graft
occlusion (18%), stent graft stenosis (10%), AAA enlarge-
ment (8%), type III endoleak (6%), rupture (2%), and 12%
other (migration, undetermined endoleak, kinking, etc.).
Freedom from aneurysm rupture and conversion to OSR
through to ﬁve years was 98.6% (95% CI 97.8e99.4%) and
97.9% (95% CI 96.7e99.1%), respectively.Aneurysm sac diameter change through to ﬁve years
Fig. 4 shows the annual change in the aneurysm sac
diameter over each year of follow up by either (i)s for ENGAGE Subjects
At 3 years % (m/n)2 At 4 years % (m/n)2 At 5 years % (m/n)2
12.2% (90/740) 12.5% (82/654) 11.3% (61/542)
0.2% (1/422) 0.0% (0/380) 0.0% (0/291)
0.0% (0/423) 0.3% (1/381) 0.3% (1/291)
0.0% (0/415) 0.3% (1/371) 0.7% (2/284)
0.0% (0/423) 0.3% (1/381) 0.3% (1/292)
0.4% (3/681) 0.3% (2/594) 0.2% (1/485)
0.6% (4/678) 0.7% (4/590) 0.0% (0/476)
10.6% (75/705) 10.3% (63/614) 9.4% (47/501)
1.4% (10/705) 2.0% (12/614) 1.8% (9/501)
0.7% (5/705) 0.7% (4/614) 1.6% (8/501)
0.7% (5/705) 1.5% (9/614) 0.4% (2/501)
8.5% (60/705) 7.7% (47/614) 7.2% (36/501)
0.1% (1/705) 0.2% (1/614) 0.4% (2/501)
0.0% (0/705) 0.0% (0/614) 0.0% (0/501)
Days % (m/n)4 1097-1461 Days % (m/n)4 1462-1826 Days % (m/n)4
998) 0.2% (2/893) 0.8% (6/779)
998) 0.6% (5/893) 0.3% (2/779)
echnical observation at the time point visit, n ¼ number of implanted
bservations at the time point visit. For kinking, fracture, detachment,
ienced the speciﬁc event in the previous follow up visits would be
riod, n¼ number of ITT ¼ intention to treat subjects at intra-operative
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Figure 2. Cumulative Kaplan-Meier estimate of freedom from all
cause mortality through to ﬁve years. Number at risk represents
patients at risk at beginning of interval; estimate made at end of
time interval.
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Figure 3. Cumulative Kaplan-Meier estimate of freedom from
secondary endovascular procedures through to ﬁve years. Number
at risk represents patients at risk at beginning of interval; estimate
made at end of time interval.
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Figure 4. Change in maximum abdominal aortic aneurysm (AAA)
diameter through to ﬁve years in 1263 patients with abdominal
aortic aneurysms treated with Endurant stent grafts.
178 Joep A.W. Teijink et al.increase > 5 mm in diameter, (ii) stable/no change, and (iii)
decrease > 5 mm in diameter. Patients were grouped based
on their AAA diameter measurement at the yearly follow up
as compared with their AAA diameter at their one month
follow up. At ﬁve years, 89.4% (n ¼ 440/492) AAAs were
observed to have decreased in size or remained stable. At
ﬁve years, 10.6% (n ¼ 52/492) of the patients had an AAA
diameter that was >5 mm larger than at their one month
follow up.DISCUSSION
The ﬁve year follow up analysis of the full cohort
(n ¼ 1 263) of the ENGAGE registry showed several
promising outcomes. The patients in this study had a
freedom from all cause mortality through to ﬁve years of
67.4%. This is higher than a retrospective single centre re-
view of patients receiving older generation grafts, where
the all cause mortality was 52.1% at ﬁve years.32 While a
meta-analysis of the early RCTs reported a ﬁve year esti-
mated survival rate of 73.6%,8 this is expected given the
patients in the RCTs were more carefully selected than
those in the ENGAGE registry. The survival outcomes of the
ENGAGE patients is very similar to other current stent
grafts, which report ﬁve year survival rates ranging between
68.4% and 72.1%.33,34
Previous reports show patients with older generation
grafts had a ﬁve year freedom from rupture and freedom
from aneurysm related mortality of 98% and 96%, respec-
tively.32 The freedom from aneurysm rupture and aneurysm
related mortality was similar in the ENGAGE cohort at
98.6% and 97.8%, respectively, after ﬁve years. De Bruin
et al. point out that aneurysm rupture was not a frequent
cause of death for either EVAR or open repair patients in
the long term.4
The need for re-intervention is another concern for
earlier generation stent grafts.8 Freedom from re-
intervention at ﬁve years generally hovers around 80% for
EVAR patients,7,32 and the six year freedom from secondary
interventions was 81.9% and 70.4% for open repair and
endovascular cohorts, respectively, in the Dutch Rando-
mised Endovascular Aneurysm Management (DREAM) trial
(with implants occurring between 2000 and 2003).4 The
DREAM trial had strict inclusion criteria and patients with
lower anatomical complexity. The ENGAGE registry con-
sisted of older patients with higher American Society of
Anaesthesiologists’ (ASA) scores, which is associated with
an increased need for secondary interventions.35 Despite
the more challenging cohort, the ﬁve year freedom from
secondary endovascular procedures was 84.3% in the
ENGAGE registry. There still remains room for improvement
as open repair can have a freedom from re-intervention
rate above 90%.12
Endoleak and migration are serious concerns because
they can lead to further complications and so modern stent
grafts have been designed to have better sealing and ﬁxa-
tion. The ﬁve year freedom from any endoleaks and from
type IA endoleaks in the ENGAGE registry was 68.6% and
Five Year Outcomes of the Endurant Stent Graft 17995.2%, respectively. These rates are very similar to an esti-
mated 74.6% of patients free from any endoleak through to
ﬁve years and 93.2% free from type I endoleaks in a
contemporary Australian cohort.36 In the ENGAGE study,
89.4% of patients with follow up imaging had declining or
stable (61.4% declining, 28.0% stable) sac diameters at ﬁve
years. This percentage is comparable to early generation
results, where 91% of patients had declining or stable (49%
declining, 43% stable) sac diameters.32 However, more
ENGAGE patients experienced sac diameter decline than
those with the older stent grafts.
Main body graft migration was seen in one patient
within the ﬁve year follow up in the ENGAGE registry
compared with 25 cases (2.9% of patients) of clinically
signiﬁcant migration reported by Brewster et al. in their
study of earlier generation stent grafts.32 Of the 173 pa-
tients that underwent endovascular repair in the DREAM
Trial, seven (4.0%) had graft migration over a period of six
years.4 Despite the ENGAGE registry having a larger frac-
tion of patients with challenging anatomical features in
their proximal neck, graft migration was minimal. The
authors note that the imaging modality primarily used in
the 30 day and one year follow ups was CT, but at the four
and ﬁve year follow ups, duplex color Doppler ultrasound
(CDUS) was more commonly used. Both techniques are
considered comparable for aneurysm size, endoleaks, and
graft patency assessment.37 However, certain stent per-
formance measures like graft migration, kinking, or frac-
ture are difﬁcult or even impossible to detect with CDUS,
which could have resulted in an underestimation of these
events.
There are several other registries with which to put the
ENGAGE results in context, although direct comparisons are
difﬁcult given differences in stent graft device design, pa-
tient populations, and event deﬁnitions. Data from two
centres in the European C3 of the Global Registry for
Endovascular Aortic Treatment (GREAT) investigated long-
term outcomes of another current stent graft in their 248
patients.33 The overall survival and freedom from re-
intervention at ﬁve years in this two-centre cohort are
nearly identical to the ﬁve year ENGAGE results, despite the
ENGAGE patients being older and consisting of more ASA
class III and IV patients. Another large registry of patients
with multiple types of EVAR grafts implanted from 2000 to
2010 in northern California had a similar all mortality sur-
vival through to ﬁve years.38 The ENGAGE cohort had larger
pre-operative aneurysm sizes and more complex anatomies
than those in the Kaiser Permanente registry, so the similar
survival rate is encouraging.
Although patients in the ENGAGE registry had similar
freedom from secondary interventions and aneurysm
related mortality to the US regulatory approval study,39 the
freedom from all cause mortality through ﬁve years was
lower for the ENGAGE patients. These outcomes should be
expected when comparing an investigation device clinical
trial with strict inclusion/exclusion criteria with an all comer
registry. Many patients in the ENGAGE registry would not
have met the Investigational Device Exemption (IDE) clinicaltrialscreening requirements for neck length, angulation, and
iliac sealing zones as they had more complex anatomies.
This is a strength of registry data as the inclusion of patients
who may not meet IFU standards allows for a better
assessment of the real world graft performance. Treating off
label patients, particularly those with challenging neck
features, has been reported to be associated with increased
risk of Type Ia endoleaks,40,41 or increased re-in-
terventions.42 As a result, most advocate cautious use of off
label EVAR and generally reserve it for high risk patients
who still require treatment. Fenestrated grafts, chimney
techniques,43 or the use of other adjunctive devices like
EndoAnchors44 can offer alternatives so physicians can stay
within IFU guidelines.
Limitations
Registries, by nature, are observational and are not
designed to have the statistical power to draw robust
comparisons as would a RCT. Also there can be more
challenges with maintaining adherence to follow up in pa-
tient registries than in a RCT.38 For example, the imaging
follow up rate of 73.7% in the ENGAGE registry was lower
than the 87% rate in the Endurant US regulatory trial.39 The
87.8% compliance rate with clinical follow up in the
ENGAGE registry was within the 87e98% rate that has been
reported in other EVAR clinical trials.34,39,45
CONCLUSIONS
In this ﬁve year analysis of the full cohort of the ENGAGE
registry, the outcomes are positive. ENGAGE patients had
better survival and lower re-intervention rates than previ-
ous generation stent grafts and the patients also experi-
enced low rates of adverse events like endoleaks and main
body migration. Longer term follow up out to 10 years will
be necessary to compare fully the advantages of EVAR
against open repair, but in the mid-term, this modern stent
graft system has been successful in treating a large real
world cohort of patients with a wide range of anatomies.
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